Clin2
NCT06969755Possibly a fitRecruiting

Brain scans and genetics to guide early schizophrenia treatment

Schizophenia Disorder

Treatments studied

Part of Mental health clinical trials.

This study tests whether using brain scans and genetic tests can help choose the best treatment for people early in their schizophrenia. It will check if these biomarkers can predict who will respond better to medication.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
180 people
Ages
18 years to 35 years
Study type
Interventional

Who can take part

  • You are between 18 and 35 years old.
  • You have been diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder within the last few years.
  • You have taken antipsychotic medication for a total of 4 weeks or less in your life.
  • You do not have certain high-risk genetic markers or brain connectivity issues that might affect treatment.
  • You are willing to have an MRI scan and genetic testing.
  • You are not currently using substances (except nicotine, alcohol, or cannabis in mild amounts) and are not pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06700967Not yet recruiting
Using genetic testing to guide schizophrenia medication choices

This trial tests whether a genetic test (pharmacogenomics) can help doctors choose better medications for people with schizophrenia. If you've had side effects or your symptoms haven't improved with your current antipsychotic, this study may help find a treatment that works better for you.

Shanghai
NCT07626034Not yet recruiting· Phase 1/Phase 2
Brain scan study for schizophrenia treatment

This study uses a special brain scan to see how well a new medication attaches to brain receptors. It may help find better treatments for schizophrenia.

NCT07483294Recruiting· Phase 4
Brain imaging study for first-episode psychosis treatment

This study uses brain scans to find markers that can predict how well antipsychotic medications work in people having their first episode of psychosis. It aims to help doctors choose the right treatment earlier.

Glen Oaks, New York
NCT07715253Not yet recruiting· Phase 1
Brain scans to study dopamine receptors in schizophrenia

This study looks at how a specific type of brain receptor (dopamine-3) works in people with schizophrenia using special brain scans (PET). Researchers want to see how these receptors behave when you are not taking antipsychotic medication, which may help guide future treatments.

NCT05839613Not yet recruiting
Personalizing antipsychotic treatment using genetics

This study looks at how a person's genes may affect how their body processes antipsychotic medications, with the goal of helping doctors choose the best medication and dose for each person. If you are changing or starting a new antipsychotic, this study might help you get more personalized treatment.

NCT04655235Recruiting
Study brain chemical systems in people with schizophrenia

This study looks at brain chemicals involved in “glutamate” and “GABA” signaling in people with schizophrenia (and separately in healthy volunteers). It may help researchers understand what’s going wrong in the brain and guide future treatments.

Aachen, Northrine-Westphalia

Hear when a new Schizophenia Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.